TWI725041B - 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑 - Google Patents

用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑 Download PDF

Info

Publication number
TWI725041B
TWI725041B TW105121932A TW105121932A TWI725041B TW I725041 B TWI725041 B TW I725041B TW 105121932 A TW105121932 A TW 105121932A TW 105121932 A TW105121932 A TW 105121932A TW I725041 B TWI725041 B TW I725041B
Authority
TW
Taiwan
Prior art keywords
cancer
pyrazine
pyrazol
methoxyphenyl
aminopropoxy
Prior art date
Application number
TW105121932A
Other languages
English (en)
Chinese (zh)
Other versions
TW201714615A (zh
Inventor
路易斯 法蘭克 斯坦卡圖
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW201714615A publication Critical patent/TW201714615A/zh
Application granted granted Critical
Publication of TWI725041B publication Critical patent/TWI725041B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW105121932A 2015-07-23 2016-07-12 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑 TWI725041B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562196087P 2015-07-23 2015-07-23
US62/196,087 2015-07-23
US201562248408P 2015-10-30 2015-10-30
US62/248,408 2015-10-30
US201562264059P 2015-12-07 2015-12-07
US62/264,059 2015-12-07

Publications (2)

Publication Number Publication Date
TW201714615A TW201714615A (zh) 2017-05-01
TWI725041B true TWI725041B (zh) 2021-04-21

Family

ID=56551588

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105121932A TWI725041B (zh) 2015-07-23 2016-07-12 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑

Country Status (6)

Country Link
US (2) US11123326B2 (ja)
EP (1) EP3325468B1 (ja)
JP (2) JP6752878B2 (ja)
CN (1) CN107849025A (ja)
TW (1) TWI725041B (ja)
WO (1) WO2017015124A1 (ja)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763410B2 (en) 2003-11-18 2010-07-27 Ricoh Company, Ltd. Electrophotographic developing carrier, associated apparatus and methodology of classification and application
CA2571424A1 (en) * 2004-06-25 2006-02-02 Icos Corporation Bisarylurea derivatives useful for inhibiting chk1
DE102006005180A1 (de) * 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
CN103442710B (zh) * 2010-11-16 2018-05-29 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc Matl Acad Sci U S A. 2011 Feb 22; 108(8): 3336-3341 *

Also Published As

Publication number Publication date
EP3325468B1 (en) 2020-11-11
TW201714615A (zh) 2017-05-01
US20220378745A1 (en) 2022-12-01
EP3325468A1 (en) 2018-05-30
JP6752878B2 (ja) 2020-09-09
US11123326B2 (en) 2021-09-21
WO2017015124A1 (en) 2017-01-26
JP2018528172A (ja) 2018-09-27
US20180369202A1 (en) 2018-12-27
CN107849025A (zh) 2018-03-27
JP2019218361A (ja) 2019-12-26

Similar Documents

Publication Publication Date Title
AU2009333433B2 (en) Compounds useful for inhibiting Chk1
DK2364302T3 (en) TRIAZINE ANALOGS AND THE USE THEREOF AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBE
JP2013510824A (ja) セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
US8637681B2 (en) Pyrrolyl substituted dihydroindol-2-one derivatives, preparation methods and uses thereof
ES2930106T3 (es) Compuesto derivado de pirrol-piridina, procedimiento para preparar el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o el tratamiento de enfermedades relacionadas con la proteína quinasa
US9573899B2 (en) USP7 inhibitor compounds and methods of use
KR101533166B1 (ko) Ｃｈｋ１ 억제에 유용한 화합물
WO2017189893A1 (en) 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
KR20160067946A (ko) 구조적으로 제한된 PI3K 및 mTOR 억제제
JP2021527692A (ja) Ｏａｔ３の阻害剤を用いた神経変性に関連する状態の処置方法
TWI725041B (zh) 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
EP2714689A1 (en) Amino-substituted-alkyloxy-benzo[e]pyrido[4,3-b]indole derivatives as new potent kinase inhibitors